Table 1.
Published in vitro EC50 acute infection values for various ARV drugs in primary macrophage cell cultures and the calculated ME scores
| ARV drug | Acute infection in macrophages EC50, nM | ME scorea |
|---|---|---|
| NRTI | ||
| Abacavir sulfate | 300 | 3 |
| Didanosine | 50 | 20 |
| Emtricitabineb | 80 | 12.5 |
| Lamivudine | 20 | 50 |
| Stavudine | 240 | 4 |
| Tenofovir disoproxil fumarate | 20 | 50 |
| Zalcitabine | 3 | 333 |
| Zidovudine | 20 | 50 |
| NNRTI | ||
| Delavirdine | 10 | 100 |
| Efavirenz | 10 | 100 |
| Nevirapine | 50 | 20 |
| Protease inhibitor | ||
| Amprenavirc | 10 | 100 |
| Indinavir | 60 | 17 |
| Nelfinavir | 80 | 12.5 |
| Ritonavir | 120 | 8.3 |
| Saquinavir | 50 | 20 |
| Fusion inhibitor | ||
| Enfuvirtide | 20 | 50 |
a
(1/median effective concentration [EC50])×1,000.
b
Unpublished data from the laboratory of RFS.
c
Amprenavir values used as an surrogate for fosamprenavir, a prodrug of amprenavir. Adapted with permission from [18].
ARV, antiretroviral; ME, monocyte efficacy; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.